Bristol Myers Squibb said Jan. 14 it voluntarily will let 340B covered entities buy Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through specialty pharmacies in the company's limited distribution network for the drugs. BMS acquired the drugs in 2019 when it acquired Celgene. In 2017, HRSA told Celgene it had to ensure that 340B entities could buy the drugs at 340B price through the same limited distribution network.

Exclusive: Nearly Five Years Before BMS Voluntarily Opened Up Myeloma Drug Network, HRSA Told Celgene it “Must Ensure” Entities Could Buy at 340B Price

The U.S. Health Resources and Services Administration (HRSA) told drug manufacturer Celgene nearly five years ago the company “must ensure” that covered entities could buy its cancer drugs Revlimid, Pomalyst, and Thalomid at the 340B ceiling price through Celgene’s limited distribution network for the drugs, according to documents obtained by 340B Report under a Freedom of Information Act (FOIA) request.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report